• Report notes that global mergers and acquisition will continue into new year
• ACP performs months of due diligence before acquiring any properties
• Company exploring land acquisition, project development strategies for expanding operations to two more states this year

Mergers and acquisitions (M&A) appear to be a key component for companies looking to grow, with a recent 2022 Global M&A Trends Report indicating that M&A will continue in the new year (https://ibn.fm/BWtXR). Contending for first place in the U.S. cannabis industry, American Cannabis Partners (“ACP”) relies on proven strategies such as mergers and acquisitions to strengthen its position in a competitive market. “Through an analysis of M&A deal activity across seven to thirteen sectors, with breakdown for each region, the [Global M&A Trends Report] concludes that we should expect further, unprecedented global growth in 2022,” the article stated. “While the pandemic has continued to impact the wider market and M&A deal terms over the course of 2021, its impact has diminished from the preceding year. Across nearly all regions, practitioners agreed that due diligence was of paramount importance to doing deals in 2021.” Due diligence is a top priority for ACP; on its website, the company notes that it “performs months of due diligence before acquiring any properties. Our sights are set on listings in cannabis friendly states, cannabis population demand, agricultural zoning, available licenses, and market value. Land and equipment are purchased in full to keep American Cannabis Partners debt free, tangible, and liquid available. After acquisitions, cost-effective measures are taken to update and appraise properties to increase market value” (https://ibn.fm/HfswI). ACP CEO Stephen Jordan echoed this philosophy when he noted that the company focuses on “‘assets, assets, assets — and then build(s) the operations out,’ a rare approach in the cannabis industry where most companies create a product first and if something happens where they are unable to make that product, they go under” (https://ibn.fm/qZ0p0). The company recognizes that state and federal regulations can fluctuate wildly, but as a multistate operator, ACP can pivot within the fluctuations of each state’s laws. This focus on maintaining the ability to liquidate, move and survive is a fundamental strategy that allows American Cannabis Partners to protect its shareholders. ACP is in the process of exploring land acquisition and project development strategies for expanding operations to additional states this year. With a total of 12 cannabis licenses, including 20,000 square feet of cultivation licenses in California and 540,000 square feet of cultivation licenses along with one retail license in Michigan, ACP is committed to becoming a leader in the U.S. cannabis industry. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs
• Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet Delic, media properties providing education on psychedelics; and DELIC Labs, a federally-authorized research facility
• The company’s CSO has spoken at a number of conferences on the importance of controlling the extraction production processes for cannabis, most recently at the annual Emerald Conference where he addressed artificial intelligence improvements
• U.S. health agencies have reported a four-fold increase in mental health concerns during the ongoing COVID-19 pandemic, demonstrating the rising need for responsive treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is showcasing the scientific talent driving its efforts to improve the production processes throughout the cannabis value chain for more effective use of the plant’s chemical properties, as demonstrated by DELIC Labs’ President and Chief Science Officer Dr. Markus Roggen’s presentation on Delic’s craft cannabis extraction research Feb. 28 at the annual Emerald Conference (https://ibn.fm/Ex7tl). Roggen’s presentation on “Artificial Intelligence for Craft Cannabis Products” highlights the lab’s experimental studies on the extraction behavior of solvents in developing a machine learning algorithm that can optimize extraction processes autonomously (https://ibn.fm/I9nnz), building on the company’s long-range efforts to increase control over production processes that were addressed by Roggen at CannMed a few years ago in a speech subsequently shared on YouTube (https://ibn.fm/ROCBg). DELIC Labs is a federally authorized psilocybin and cannabis research laboratory that dedicates its efforts to improve extraction, analytical testing, and chemical processes. The laboratory’s R&D solutions for product lines and new intellectual property (“IP”) serve as the engine for the company’s overall ecosystem. In addition to the scientific backbone of the ecosystem, Delic’s health operations aim to help people live better lives through the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC”) operating a dozen locations strategically located in secondary cities to improve accessibility and reach and serve the greatest number of patients. The clinics have overseen thousands of mental health treatments to date, and the company plans to open 14 more clinics by mid-2023, according to a January corporate update (https://ibn.fm/aWT2E). The third component of Delic’s ecosystem is the company’s educational and promotional efforts through a variety of media outlets, including its Reality Sandwich digital magazine, a public education platform that provides psychedelic guides and news, streaming episodes on Delic Radio, and the company’s psychedelic wellness summit — Meet Delic — which drew more than 2,000 in-person attendees when it debuted in Las Vegas last fall (https://ibn.fm/7lLWX). Delic’s scalable approach to making psychedelic-based treatments a regular part of emotional health management is aimed at “giving people their best selves back.” During the advent of the COVID-19 pandemic, mental health concerns have only intensified. As noted in a Desert Sun report, 4 in 10 U.S. adults have reported symptoms of anxiety or depression during the pandemic — a four-fold increase from 2019. “While vaccines afford significant immunity from the worst physical effects of the virus, the trauma of widespread death, illness and isolation is considerably harder to inoculate against,” the report states (https://ibn.fm/Ft7dF). “At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” Delic Co-founder and CEO Matt Stang stated during the corporate update. “There are 51.5 million Americans who have experienced a mental health condition and the ongoing pandemic has only exacerbated the crisis. We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects. … Delic is well-positioned for growth and profitability in 2022 and beyond.” For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• GreenBox will build the first banking-as-a-service initiative, catapulting the company into the same playing field as other major FinTech-driven brands
• CEO Fredi Nisan said the initiative will be a game changer for the company, expanding its capabilities and potential customer base, while also serving as a significant driver of revenue growth
• The partnership will provide additional services to existing clients on a single, seamless platform with a full suite of services that position the two companies to be a vertically-integrated full solution service

GreenBox POS (NASDAQ: GBOX), an emerging financial technology (FinTech) company that leverages proprietary security and token technology to build customized payment solutions for businesses, has announced entering a licensed partnership with Cross River. Cross River is a technology-driven infrastructure provider offering embedded financial solutions. The licensed partnership brings GreenBox closer to building compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving, and dynamic market worldwide (https://ibn.fm/y5Inb). Cross River is known for merging innovative state-of-the-art technology capabilities with the expertise of traditional banking, which is currently powering multiple leading FinTech companies across the United States. Through the partnership with Cross River, GreenBox will bring to realization its first banking-as-a-service initiative. This strategic move by GreenBox will catapult the company into the same playing field with other major FinTech-driven brands. “This was an important and necessary first step towards the launch of banking as a service which we believe will be a game-changer for GreenBox as it will radically expand our capabilities and the vast universe of potential customers, with a customer-inspired, technology-driven and combined offering,” GreenBox CEO Fredi Nisan said, talking about the partnership. “Not only will we eventually be able to offer all our existing merchant clients cutting edge banking services, but we can also open these solutions to strategic partnership and enterprises seeking white label solutions. We expect this to be a significant driver of revenue growth.” The infrastructure and payment rails provided by Cross River will enable GreenBox to open accounts (custodial, reserve, and operating accounts) for customers, which can be managed with a full suite of tools, all of them powered by Cross River. Resulting advantages include the potential creation of new channels to add customers, leading to great levels of revenue growth. Combining GreenBox technology with Cross River’s infrastructure will provide additional services to existing clients on a single, seamless platform with a full suite of services. “Joining forces with GreenBox highlights Cross River’s ability to do what we do best: empower innovative and responsible fintech companies to provide their customers with access to transparent, secure, and reliable financial solutions,” Cross River’s EVP and Head of FinTech Banking, Adam Goller, said. “We’re elated to be leading the way with GreenBox in advancing the digital finance landscape into a hassle-free, all-inclusive, and technology-centered experience for businesses and consumers alike.” Nisan also underlined that Cross River was the perfect partner to launch this ambitious initiative with, given their expertise in banking technology. “This represents yet another example of us executing against our master plan for expansion, with a trusted, tech-forward bank whose mission is aligned with our own. Together, we will be a disruptive force in the FinTech landscape, enabling the sustainable, long-term value our shareholders expect.” The initial phase of the partnership will serve as a foundation for banking-as-a-service solution. This offers customers a superior experience through a centralized hub under a user-friendly platform. The overall offering will roll out in multiple phases, delivering exceptional advantages like security, efficiency, and rapid transaction settlement across a wide range of capabilities. For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX

• The company recently announced a strategic private placement executed with agribusiness Nurture Healthy Foods to bring in just over $5 million in capital at $0.75 for M&A and general operations
• Plant-based consumer products brand builder Eat Well Investment Group Inc. is a growing investment company operating in North American markets
• Eat Well’s agreement with Nurture Healthy Foods includes an economic interest in Eat Well’s majority ownership of Amara Organic Foods, a growing manufacturer of plant-based baby foods
• The company’s products are also gaining increased distribution through companies such as Walmart, Whole Foods, Sprouts Farmer’s Market, Loblaws and HEB Grocery Company (H-E-B)

Vertically integrated plant-based foods investment company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF), is securing new capital at $0.75 per Unit for M&A and general working activity, according to a recent announcement that notes not only a new round of private placement funding but also the sale of an interest in its portfolio company PataFoods, Inc. “This morning we shared with the markets that Nurture Healthy Food LLP has come in for a strategic private placement with us, approximately $5 million,” Eat Well CEO and Director Marc Aneed told Shoran Devi in a Feb. 15 interview with The Power Play (https://ibn.fm/vChpO). “The team at Nurture are like-minded to us. They are ESG (Environmental, Social and Governance factor)-driven, they are business builders and they are all about our mission, which is to feed families globally,” Aneed added. “This gives us strategic growth internationally through commercial, retail and distribution opportunities, as well as looking at deeper parts of their agribusiness portfolio and their plant-based solutions that we can bring to the world.” Eat Well Investment Group has customers in over 35 countries already, but the agreement with Nurture Healthy Food will help the company’s customer and distribution relationships “exponentially move into the future,” Aneed said. The company generated nearly $60 million (Canadian) in revenue last year during a breakout year when it acquired plant-based ingredients processor Belle Pulses and plant-based food creator Sapientia and added an OTC listing in the United States to its Canadian Stock Exchange profile. Eat Well expects to report top-line earnings between $90 million and $110 million by the end of this year. “We couldn’t be more excited to find ways to blueprint our distribution growth throughout South America, Latin America with their strength that they (Nurture Healthy Food) have today in retail,” Aneed said. Eat Well acquired 51 percent ownership of Pata Foods (dba baby food brand Amara Organic Foods) last year with an option to obtain up to 80 percent if it wishes. Amara reported 533 percent revenue growth during 2021 and was named Amazon’s top new release (https://ibn.fm/WmhXa). The economic interest in Amara that Eat Well sold to Nurture entitles Nurture to receive 8 percent of the net proceeds or other property received by Eat Well if a liquidation event occurs in regard to Amara, such as a merger or the sale of any portion of the company’s overall equity interest in Amara, as well as 8 percent of any dividend declared and paid by Amara to Eat Well (https://ibn.fm/OtQ9h). Eat Well’s growth strategy includes recent announcements that Amara will be distributed through over 400 Walmart stores in Canada and online through Walmart’s e-commerce platform, as well as through Loblaws’ Canadian stores nationwide and through 200 of food retailer HEB Grocery Company (H-E-B) stores in the United States. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005
• This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds
• Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea
• The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term

Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a psychoactive experience, has been gaining popularity recently. It has been lauded as a viable method of treating specific mental health conditions such as depression, anxiety, and attention-deficit/hyperactivity disorder (“ADHD”). However, more research is needed to confirm its safety and efficacy. One of the main issues that have been highlighted is the substantial medical risk involved with microdosing. Psilocybin, for instance, has shown a binding affinity to the 5-HT2B receptor, which is, in turn, linked to heart valve tissue fibrosis. As such, its consumption, over a long period, could present a patient with cardiovascular health concerns, a legitimate risk that ought to be considered (https://ibn.fm/O0mS4). In a significant move that remedies the situation, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced its latest drug discovery and its first of many for the new year, MYCO-005. Essentially a novel molecule in its family of psilocin analogs, MYCO-005 has proven to have potentially heart-safe microdose enabling properties while addressing the shortcomings and limitations associated with the first-generation compounds. “We are very excited about our MYCO-005 family of molecules,” noted Josh Bartch, the Chief Executive Officer (“CEO”) of Mydecine. “Not only have we made improvements to this second generation of compounds to specifically address concerns for medical use, like onset time and shelf stability, but now we believe we have also identified a microdosing compound that is safer than what’s currently available on the market,” he added. Mydecine’s patent-pending dermal route to administration offers more control over the drug while also potentially eliminating undesirable properties including, but not limited to, nausea. This is achieved by bypassing the digestive system. Going forward, the company seeks to explore this new feature and study its patent-pending skin permeation technology to produce a low-dosed, time-released patch that does not result in hallucinations for the patient. “This is one of the many exciting drug discoveries we look forward to sharing in the near term,” noted Mr. Bartch. This significant milestone for Mydecine proves its commitment to transforming the treatment of mental health and addiction disorders, particularly with psychedelics. It also shows its commitment to research and creating value for its shareholders. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success
• The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products
• Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls
• The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation

Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products and medication by increasing their bioavailability, speed of onset, and brain absorption, is currently targeting multiple large market opportunities, ranging from cardiovascular drugs, antivirals, human hormones, and phosphodiesterase inhibitor (“PDE5 inhibitor”) formulations to nicotine replacement, and cannabidiol (“CBD”). “We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $10 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success,” Lexaria CEO Chris Bunka wrote in a January 27 annual update to its stakeholders (https://ibn.fm/0zK6O). The company’s multifaceted operational approach leverages its versatile and disruptive DehydraTECH(TM) technology, which is currently protected by a total of 23 granted patents worldwide. Designed specifically for delivering fat-soluble drugs and active pharmaceutical ingredients, DehydraTECH pairs the active ingredients with a fatty acid oil, such as high oleic sunflower oil. It then applies the resultant compound to food or carrier particles such as sorbitol or gum Arabic before a dehydration synthesis procedure is performed. The final step entails rendering the product as powder or liquid (https://ibn.fm/Pzile). “Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website reads. And multiple studies have supported this statement. Most recently, Lexaria announced positive results from an animal study, PDE5-A21-1, investigating DehydraTECH processing of PDE5 inhibitor sildenafil for potential application in the management of erectile dysfunction. Conducted at a US-based, third-party independent laboratory, the study involved 20 male Sprague-Dawley rats, half of which were treated with one dose of the DehydraTECH-sildenafil, with the rest receiving generic concentration-matched, control-sildenafil formulation. The PDE5-A21-1 study showed that DehydraTECH technology delivered 74% more sildenafil into the bloodstream on average than the control just four minutes after dosing. After another three minutes, the DehydraTECH-sildenafil formulation reached an average blood level higher than the control formulation achieved at any point during the study. Further, the DehydraTECH-sildenafil reached a maximum concentration in the bloodstream (“Cmax”) that was approximately 70% higher and at a 25% faster rate than generic sildenafil control formulation. With the common complaint among many sildenafil users being that it is slow to act, the findings of the PDE5-A21-1 study could usher a new dispensation as regards the development of better and faster-acting sildenafil oral formulations. The results supported further investigation involving a larger number of animals. Overall, Lexaria aims to leverage positive results from such studies to journey step by step toward removing risks associated with commercialization and regulation. Eventually, the company says, with enough positive data, the formula will tilt in its direction. “Our R&D focus for 2021 was to investigate DehydraTECH-CBD for possible hypertension and heart disease applications; to further our knowledge of DehydraTECH-nicotine as a replacement for damaging and deadly lung-based absorption methods; and to learn whether DehydraTECH would be compatible with antiviral drugs. We were successful in each of these primary areas of investigation,” Bunka wrote. Looking ahead to 2022, Lexaria plans to launch three major studies between March and April: the human sublingual/buccal tissue study (oral nicotine), the animal seizure study (“CBD”), and its most ambitious study yet, the 6-week human hypertension study (“CBD”). The goal of these three studies is to generate sufficient data to support either regulated IND-type applications or influence corporate partnerships. At the same time, Lexaria will also be conducting several smaller studies throughout the year and will update shareholders when appropriate. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• PlantX recently added a new YouTube educational series to its channel- “Medically Speaking”
• This new series will complement the company’s growing body of resources, including podcasts, blogs, and articles posted on its website
• Mr. Sean Dollinger, the Founder of PlantX, recognizes that there is a growing need and demand for engaging plant-based educational opportunities
• The company seeks to capitalize on this education-oriented approach to empower its audience and help them overcome barriers to change in their journey towards adopting a plant-based lifestyle

It is estimated that around 2 billion people globally live on a largely meat-based diet, while 4 billion thrive on a mostly plant-based diet. Between 2014 and 2017, there was a 500% increase in the number of vegan consumers in the United States. Additionally, there was an 11% increase in retail sales of plant-based foods from 2018 to 2019 (https://ibn.fm/liSI4). These figures show a growing demand for plant-based products and the increasing adoption of a plant-based lifestyle. PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), an enterprise that focuses on everything plant-based, recognizes this growing trend and looks to capitalize on it going forward. So far, PlantX offers more than 5,000 plant-based products to customers across North America. Additionally, it provides meal and indoor plant deliveries for an all-around experience. The company’s goal is to become the digital face of the plant-based community, covering everything from retail to community-building efforts, new product offerings, and, most importantly, education. PlantX is banking on an education-oriented approach to not only retain its existing customers but also attract new ones. Its educational content, so far, covers the value of plant-based living, cooking recipes, and podcasts that feature experts in the industry. The company is confident that with this ever-growing body of content, its audience will get access to all the necessary knowledge needed to achieve their plant-based goals. “We have seen a tremendous global shift to plant-based diets in recent years, and this trend continues to rise. As the interest in plant-based diets increases, so does the need and demand for engaging plant-based educational opportunities,” noted Sean Dollinger, Founder of PlantX (https://ibn.fm/S61lh). The company’s most recent addition to its YouTube educational series, “Medically Speaking,” seeks to provide evidence-based information to bridge knowledge gaps and clarify potential questions in the plant-based space. This new series also aims to offer creative solutions to overcome plant-based challenges, with insights from trusted healthcare professionals. This approach also translates to regularly updated blogs and articles on its website, intended to offer consumers value and uplift the plant-based community. “Whether you follow a plant-based lifestyle or you’re a flexitarian, you can count on our news to guide you on this journey,” states its website (https://ibn.fm/TXD6Z). Going into 2022, PlantX hopes to win big with its education-oriented approach. Mr. Dollinger and the rest of the company’s leadership are confident that this method will bear fruit as time progresses. The company has achieved a lot in empowering people and helping them overcome barriers to change with its content so far. It hopes to take things even further in this new year and impact even more lives while at it. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Friendable’s offering of the Fan Pass Live artist platform and acquisition of Artist Republik provide musical artists with an “anti-label” set of tools to produce, perform, and distribute music
• Pulling music from Spotify is not always the best option, especially when artists need that revenue
• Fan Pass Live offers artists an alternative to lower-paying platforms, allowing artists to keep 100% of ticket sales and tips while receiving revenue from other sources on the platform
• Friendable posts additional contests on Instagram for artists on the platform to participate in to win monetary and physical prizes

The controversy surrounding the recent string of artists removing their music from Spotify has left behind an unsavory view of music streaming platforms. The controversy began when podcaster Joe Rogan provided misinformation about the COVID-19 vaccine during his podcast. This misinformation sparked a letter (with an ultimatum) from music legend Neil Young, which was posted online and then taken down immediately. Still, Spotify began the process of pulling Young’s music, per the ultimatum. Young wasn’t the only one who had reservations about The Rogan Experience podcast, with doctors sending letters to Spotify trying to mitigate what they deemed as misinformation from the podcast. The entire situation has snowballed, becoming bigger and bigger, and more artists chose to leave the platform. The entire situation has shed light on how artists on the platform are compensated, especially after the unveiling of Rogan’s $200 million contract with Spotify. The music industry is primarily controlled by three record labels – Sony Music, Universal Music, and Warner Music, with Sony and Universal owning 8% (Sony – 5.7%) of Spotify. This percentage owned by Sony results in a $1.1 billion stake in the revenue resulting in artist’s streaming. Most artists would have to have 2,197 streams per hour to equal one hour minimum wage in the United States. Meanwhile, the CEO of Spotify, Daniel Ek, is worth over $4 billion. For artists, especially those considered independent, removing music from the Spotify platform can be more detrimental than beneficial. Earning revenue, at any rate, is a must for any artist. Even those who remain on the Spotify platform earn something, resulting in earning more than if they were to pull their catalog from the streaming service. Spotify isn’t the only answer for independent artists who want control of their music without the major labels dictating their revenue earnings. The Fan Pass Live artist platform, the flagship offering of Friendable (OTC: FDBL), has emerged as a viable full-service alternative for independent artists. Friendable recently completed the acquisition of Artist Republik, creating an all-in-one opportunity for independent artists looking for a virtual stage to stream music, as well as promotion, merchandise, distribution, and more. The Friendable founders, Robert A. Rositano, Jr. and Dean Rositano, are no strangers to the music industry. Having been a musician himself, Dean understands the need for artists to make money while doing what they love – a passion that both brothers share. The result of this passion? Fan Pass Live’s unique revenue structure that allows the artist to earn through:

• Ticket sales and tips (100% goes back to the artist)
• Merchandise sales
• Beats/Sample packs
• 40% of the subscription pricing from fans on a recurring monthly basis
• And more!

In addition to the steady revenue above, artists also have the opportunity to compete in monthly contests for additional cash or prizes. February’s contest, as promoted on Instagram (@fanpasslive), is called “Ticket to Win.” The three artists with the highest number of ticket sales will be awarded $500 for first place, $250 for second place, and $150 for third place, in addition to their monthly revenue totals and ticket sales, tips, etc. Additionally, any artists who purchase Fan Pass gear through the merchandise shop and use the code ‘RAFFLE’ at checkout will be entered to win their own custom merchandise collection (a $500 value). Friendable is making waves in the music industry by providing artists with an “anti-label” experience. From creating music to selling out virtual concerts, and promotion to distribution, the collaboration of Fan Pass Live and Artist Republik under the Friendable name is changing how artists get paid, heard, and promoted. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Silicon Valley-based security robot developer Knightscope manufactures a variety of autonomous models steeped in technological tools to patrol and monitor client properties on a 24/7 basis
• Knightscope’s clientele have provided testimonials to local government officials at times, noting the robots’ effectiveness in helping to reduce crime rates
• The company’s robots primarily provide a presence in at-risk sites to offer safety through surveillance, but they have also delivered useful data to law enforcement officers investigating a variety of crimes
• The need for autonomous security robot sentries is apparent in the increase in violent crimes during the past couple years, which included a 30 percent jump in the murder rate between 2019 and 2020

Reports of increasing crime rates during the course of the COVID-19 pandemic the past two years have led officials to question the trend’s causes and search for potential solutions. The Centers for Disease Control and Prevention (“CDC”) reported that the murder rate in the U.S. rose by 30 percent between 2019 and 2020, for example, marking the largest single year increase since at least 1905 but possibly ever, as noted this month by The Hill (https://ibn.fm/DeoeA). In a report by the Associated Press, criminologist James Alan Fox described the spike in violence as a “unique” situation engendered by the novel, global pandemic (https://ibn.fm/0wroi), while National Center for Health Statistics chief of mortality statistics Robert Anderson challenged the idea that the violence might be caused by pandemic stress. “You really have to look at other patterns and there certainly seems to be a correlation between the two but as we know correlation is not causation,” Anderson stated in a CDC interview (https://ibn.fm/oPsHr). Autonomous security robot (“ASR”) developer Knightscope (NASDAQ: KSCP) has devoted years and over $100 million in funding to building a cadre of ASR robot sentries designed to help discourage such crime, and as Knightscope’s corporate client list grows, so too do reports of clients’ satisfaction with the robots. The ASRs establish a continuous presence at their assigned locations, recording a large variety of data and relaying it electronically to an operations center according to the clients’ select needs. Some of the models are mobile, while another is stationary — again, providing options to clients as they deem best suits their purposes. “The K5 robot (outdoor model) is having a positive impact on crime and nuisance activity at Salt Lake Park, which is reducing the instances of police activity at the park,” Huntington Park (Los Angeles County) City Manager, Ricardo Reyes, and Police Chief Cosme Lozano wrote to their city council in 2020, as noted in Knightscope’s description of its ASR models’ interdiction effects (https://ibn.fm/lrDYC). Those effects include deterring crime and vandalism in a Las Vegas residential parking garage, providing high-definition video and license plate detections over a four-month period in response to a law enforcement agency’s investigation, providing evidence of two burglaries and felony property damage that led suspects to confess their involvement to a law enforcement agency, establishing improvements in feelings of security for nurses and doctors accompanied by the ASRs as they walked from work to their parked cars after dark, and identifying a heat anomaly in a hair styling kiosk that helped officers prevent a major fire — as well as several other incidents cited by the company. Some media outlets have questioned the effectiveness of the ASR patrols since Knightscope began trading publicly on the NASDAQ exchange in January (https://ibn.fm/MnoPd). One report last year, citing the difficulty in quantifying how much of a difference the security robots have made, nonetheless noted that Knightscope co-founder and Executive Vice President Stacy Stephens said that the company has experienced client renewals from 2, to 3, to 4, and even 5 years. By a unanimous 5 to 0 vote, the City Council of Huntington Park approved the renewal of the Knightscope Autonomous Security Robot contract for an additional two-year term. Chief Lozano stated at the July 6, 2021, Council meeting, “the reality is that a patrol officer cannot do what modern technology can do through the use of this robot.” The NBC report quoted Robert Krauss, the vice president of public safety at the Pechanga Resort Casino north of San Diego, who said the casino had been using six ASRs for three years and wasn’t sure “how useful they have been in terms of stopping crime, but … that the robots have been able to identify panhandlers and other people that the casino wants to exclude,” as well as helping to resolve a costly lawsuit by providing video footage of a woman who fell and claimed the casino was at fault. “You never know how many [bad actors] you’ve prevented by placing [the robots] there, so I don’t know what we’ve prevented. But I can tell you we’ve never had anything serious. … Going forward, I will probably add one or two more,” Krauss told the NBC reporter (https://nnw.fm/9IOnh). (https://ibn.fm/kF41S). For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Flora Growth is a cannabis cultivator and distributor with a large cultivation site in central Colombia’s favorable growing climate
• Flora Growth recently announced an agreement with Israeli product distribution company Artos Ltd. to sell Flora’s high-THC cannabis flower to Israelis
• Colombia legalized the international export of cannabis flower last year for use in health and wellness industries
• Israelis comprise a large base of medical marijuana users and cannabis-based business enterprises
• Colombia and Israel began strengthening ties last year for promoting entrepreneurial innovation, and the agreement between Flora Growth and Artos builds on those state efforts

Cannabis cultivator and brand builder Flora Growth (NASDAQ: FLGC) is continuing its push toward global market distribution efforts with the announcement that the company will sell about 3,600 kg of dried high-THC cannabis flower to Israel through an agreement with Israel-based consumer products distributor Artos Ltd. Flora Growth owns and operates a 100-hectare (about 247-acre) cannabis cultivation site in central Colombia, a country renowned for its ideal growing conditions. The company leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage on a global basis. “As Cosechemos continues to reach full-scale commercial production, our team remains focused on increasing our presence in international cannabis markets through distribution agreements that will serve as a gateway into the markets,” Flora Growth CEO Luis Merchan stated as part of the company’s announcement (https://ibn.fm/WJQoD). Artos was established 15 years ago with the select purpose of increasing Israeli citizens’ access to global consumer products. The company has a network of over 4,000 distribution points across the country and reports over $50 million in revenue from sales of non-cannabis products. “With Artos’ extensive distribution network, this agreement will ensure that safe, high-quality cannabis products are provided to the Israeli cannabis market and offer a valuable source of health and wellness products to the country,” Merchan stated. Cosechemos boasts legal operation in a country with one of the world’s largest cut-flower industries, operating in several regions 365 days a year with over 12.5 hours of natural sunlight and a labor force with substantial agricultural experience. Cosechemos has natural water springs onsite and its international distribution strategy is to establish Flora Growth as a leader in plant-based wellness and lifestyle brands in a variety of countries in the Americas and Europe. The Artos agreement builds on Colombia’s state efforts to build ties with Israel for entrepreneurial innovation following the country’s legalization of dried cannabis flower exports last July. Colombian President Ivan Duque stated at the time that while illegal cocaine production has been a devastating trade for his country in terms of criminality and environmental destruction, cannabis is seen as a much more beneficial product when its derivatives are used for everything from medical treatments and food production to cosmetics. The country is not green-lighting exports for recreational purposes, he told NBC News (https://ibn.fm/GiwlQ). The same report noted that more than 100,000 Israelis are licensed medical marijuana users, and that the country has more than 110 cannabis tech companies, mostly in the health sector, that have attracted nearly $350 million in investment since 2015. It also noted that Israel is among the largest importers of medical cannabis flower in the world. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC